Biotech Values

[ThomasS]

MNTA: Momenta Pharmaceuticals to Present M402 Preclinical Data At Upcoming AACR Meeting
M402, a Rationally Designed Molecule With a Novel Mechanism of Action, Inhibits Tumor Metastasis in Animal Studies
{First data on their oncology candidate.}

http://finance.yahoo.com/news/Momenta-Pharmaceuticals-to-pz-14926283.html

Momenta Pharmaceuticals, Inc. (NasdaqGM:MNTA - News), a biotechnology company specializing in the characterization and engineering of complex mixture drugs, today announced that preclinical data for its novel drug candidate, M402, (formerly M-ONC 402) will be presented at the 100th Annual Meeting of the American Association for Cancer Research (AACR). The meeting will be held April 18-22, 2009 in Denver, Colorado.

The following two posters will be presented:

``M-ONC 402 - A Non-Anticoagulant Low Molecular Weight Heparin Inhibits Tumor Metastasis'' (abstract #281)

-- Poster Session: Sunday, April 19, 2009 from 8:00 AM - 12:00 PM

``M-ONC 402 - A Novel Low Molecular Weight Heparin (LMWH), Interacts with Heparin Binding Proteins and Inhibits Metastatic Seeding of Tumor Cells in Mice'' (abstract #5005)

-- Poster Session: Wednesday, April 22, 2009 from 8:00 AM - 12:00 PM